BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37354253)

  • 21. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
    Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
    Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.
    Jones AC; Daniells CE; Snell RG; Tachataki M; Idziaszczyk SA; Krawczak M; Sampson JR; Cheadle JP
    Hum Mol Genet; 1997 Nov; 6(12):2155-61. PubMed ID: 9328481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
    Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.
    Guilmette JM; Nosé V
    Adv Anat Pathol; 2019 Jan; 26(1):13-30. PubMed ID: 29912000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC).
    Machacek ME; Wu CL; Cornejo KM
    Semin Diagn Pathol; 2024 Jan; 41(1):8-19. PubMed ID: 37993384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex.
    Al-Saleem T; Wessner LL; Scheithauer BW; Patterson K; Roach ES; Dreyer SJ; Fujikawa K; Bjornsson J; Bernstein J; Henske EP
    Cancer; 1998 Nov; 83(10):2208-16. PubMed ID: 9827727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.
    Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
    Cancer Cytopathol; 2018 May; 126(5):326-335. PubMed ID: 29451738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroendocrine tumors of the pancreas: current concepts and controversies.
    Reid MD; Balci S; Saka B; Adsay NV
    Endocr Pathol; 2014 Mar; 25(1):65-79. PubMed ID: 24430597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype/phenotype correlation in 123 Chinese patients with Tuberous Sclerosis Complex.
    Ng SY; Luk HM; Hau EW; Cheng SS; Yu KP; Ho S; Mok MT; Lo IF
    Eur J Med Genet; 2022 Oct; 65(10):104573. PubMed ID: 35918040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
    Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
    Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding the Spectrum of Colonic Manifestations in Tuberous Sclerosis: L-Cell Neuroendocrine Tumor Arising in the Background of Rectal PEComa.
    Kolin DL; Duan K; Ngan B; Gerstle JT; Krzyzanowska MK; Somers GR; Mete O
    Endocr Pathol; 2018 Mar; 29(1):21-26. PubMed ID: 28733877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biallelic TSC gene inactivation in tuberous sclerosis complex.
    Crino PB; Aronica E; Baltuch G; Nathanson KL
    Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified.
    Camposano SE; Greenberg E; Kwiatkowski DJ; Thiele EA
    Ann Hum Genet; 2009 Mar; 73(2):141-6. PubMed ID: 19133941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
    Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported.
    Niida Y; Wakisaka A; Tsuji T; Yamada H; Kuroda M; Mitani Y; Okumura A; Yokoi A
    J Hum Genet; 2013 Apr; 58(4):216-25. PubMed ID: 23389244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
    Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
    Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.